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INTRODUCTION 
Diabetes Mellitus (DM) has become a popular chronic 
disease worldwide. The prevalence of DM is 8.8% 
globally and 8.6% in Southeast Asia. It has been 
increasing rapidly in low- and middle-income countries 
(Dunning et al., 2014). Based on a national survey, in the 
year 2030 number of DM cases Indonesia estimated 
about 21.3 million (Ministry of Health of the Republic of 
Indonesia, 2018). 
Uncontrolled DM treatment is a serious problem that 
might be caused by microvascular and macrovascular 
complications (Chawla et al., 2016; Cade, 2008) and death 
(American Diabetes Association, 2015). Cardiovascular 
disease (CVD) is the leading cause of death in patients 
with diabetes mellitus (Benjamin et al., 2017). Health 
problems in many developing countries are in 
epidemiology transition where chronic Non-
Communicable Diseases (NDCs) are major public health 
concerns due to the enormous financial burden 
associated with these diseases. Diabetes mellitus and 
hypertension were top the list of NDCs, these two 
chronic diseases are the most important risk factor for 
cardiovascular diseases (Bolarinwa et al., 2018). 
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 Abstract 
Type 2 diabetes mellitus (T2DM) is a major chronic disease that affects 
a large number of people worldwide. Hypertension is a common 
disease comorbidity among T2DM patients, and often those patients 
received polypharmacy and complex treatment in long term duration. 
This condition may lead to an increased risk of drug therapy problems 
(DTPs). This study aimed to assess and determine potential drug 
therapy problems in type 2 diabetic patients with hypertension 
comorbidity. Retrospective cross-sectional design was conducted in a 
hospital setting, especially data sources from the prescription of 
ambulatory T2DM patients with hypertension. A total of 190 patients 
were studied. More than half of the participants were female (53.68%). 
The majority age range of participants was 50-59 years (46.84%). 
Almost all antidiabetic agents were prescribed as polypharmacy 
(73.16%). Metformin was the most antidiabetic agent prescribed as 
monotherapy and combination therapy (63.16%). Almost all 
antihypertensive agents were prescribed as polypharmacy (63.26%). 
Amlodipine was the most antihypertensive agent prescribed as 
monotherapy and combination therapy (34.74%). Among the study 
participants, 56.84% have at least one of DTPs. Adverse drug reaction 
was the most frequent (47.22%), followed by ineffective drug therapy 
(29.63%). Since the potential of DTPs in T2DM patients with 
hypertension comorbidity is relatively high, early identifying, 
resolving, and preventing drug therapy problems by the pharmacist is 
needed to achieve goals of treatment. 
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Hypertension is the most common disease comorbidity 
with diabetes. The presence of hypertension with 
diabetes increases in mortality and drug therapy 
problems worldwide, with a greater risk in developing 
countries (Petrie et al., 2018; James et al., 2014). 
Hypertension and type 2 diabetes mellitus (T2DM) called 
“lethal duo” which increases the risk of cardiovascular 
disease 2- to 4-fold over both diseases themselves, such as 
heart attack, stroke, ischemic heart disease, and 
microvascular complications (Farský et al., 2018). 
Multiple medical conditions have been shown to 
contribute to drug therapy problems (DTPs) (Gangwar et 
al., 2014). Similarly, T2DM patients with hypertension 
often use polypharmacy medication and this may lead to 
the occurrence of drug therapy problems. Studies show 
that the number of DTPs per patient linearly increases 
with the increase in the number of medicines used 
(Abdulmalik et al., 2019). 
Several studies in some countries such as Malaysia, 
Ethiopia, and Nigeria about DTPs in T2DM with 
hypertension have shown that each diabetes patients 
experienced at least one of drug therapy problems (Huri 
& Wee, 2013; Yimama et al., 2018; Argaw et al., 2019; 
Hussen & Daba, 2017; Ayele et al., 2018; Ogbonna et al., 
2014). Drug therapy problems may lead to elevating 
morbidity, disability, mortality, health care cost, low 
adherence, and prolonged hospitalization (Nivya et al., 
2015; Claydon-Platt et al., 2012).  
In Indonesia, hypertension is a common comorbidity in 
T2DM patients. However, Indonesia has no adequate 
and comprehensive studies on DTPs, particularly among 
T2DM patients with hypertension comorbidity. The aims 
of this study are to determine pattern prescription of 
antidiabetic and antihypertensive agents, to assess the 
prevalence of potential drug therapy problems, and to 
identify determine of drug therapy problems among 
T2DM patients with hypertension comorbidity. 
MATERIALS AND METHODS 
This is a retrospective cross-sectional study design that 
was conducted in the inpatient ward of secondary care 
hospital in West Java Indonesia. This study has approval 
by the Awal Bros Hospital Bekasi Barat education and 
ethics committee No. 100/DIR/RSAB-BKS/1/2015. A 
total of 190 patients who admitted to the hospital from 
January until December 2014 and meet the inclusion 
criteria. The inclusion criteria were: 
1. Adult patient (≥ 40 years old) 
2. Diagnosed T2DM with hypertension comorbidity 
3. Prescribed at least one antidiabetic agent and 
antihypertensive agent 
The exclusion criteria are patients with the pregnant 
condition. Data collected from the medical record and the 
prescriptions of T2DM with hypertension comorbidity. 
The identified of DTPs was classified based on 
pharmaceutical care practice the third edition were: 
1. Unnecessary drug therapy 
2. Need additional drug therapy 
3. Ineffective drug therapy 
4. Dosage too low 
5. Dosage too high 
6. Adverse drug reaction 
7. Non-adherence/non-compliance (Cipolle et al., 2012). 
This study was performed a descriptive analysis of 
demographic characteristics, pattern prescriptions 
antidiabetic and antihypertensive agents, as well as type 
and cause of DTPs. 
 
RESULTS AND DISCUSSION 
Demographic characteristics 
As many as 190 patients included in this study. More 
than half of the patients were female (53.68%). The age 
range of the majority of patients was 50-59 years (46.84%), 
followed by 60-69 years (30.53%), 40-49 years (12.10%), 
70-79 years (8.95%), and more than 80 years (1.58%). 
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These results were in the line with Zazuli et al. (2017) and 
Ayele et al. (2018) who reported majority T2DM patients 
with hypertension comorbidity were female and age 
range under 56 years old. Contrasting to Yimama et al. 
(2018) and Argaw et al. (2019) who reported that majority 
T2DM patients and hypertension comorbidity were 
males. This result pointed risk of hypertension disease in 
T2DM patients equally between each gender. 
Prescription patterns of antidiabetic and 
antihypertensive agents 
Among the participants, only 26.84% received 
monotherapy antidiabetic. Of the total participants, 
73.16% received between two until five antidiabetic 
agents. Metformin (63.16%) followed by glimepiride 
(46.84%) were the most frequently antidiabetic agents 
prescribed as monotherapy and combination with other 
antidiabetic agents, as presented in Table I. This result 
supported by Yimama et al. (2018), Argaw et al. (2019), 
Ayele et al. (2018), and Ogbonna et al. (2014) who reported 
metformin as the most antidiabetic agent prescribed for 
monotherapy or combination. This study contrasts with 
Zazuli et al. (2017) who reported insulin was the most 
prescribed as monotherapy and combination. 
Polypharmacy antidiabetic prescriptions are one of the 
factors identified to influence non-adherence in T2DM 
patients with hypertension (Atinga et al., 2018). 
Table I. Patterns prescription of antidiabetic agents in 
T2DM with hypertension (n = 190) 
Variable category N (%) 
Number of prescription 
Monotherapy 51 (26.84) 
2 antidiabetic agents 90 (47.37) 
3 antidiabetic agents 35 (18.42) 
4 antidiabetic agents 10 (5.26) 
5 antidiabetic agents 4 (2.11) 
Type of antidiabetic agents 
Metformin* 120 (63.16) 
Glibenclamide  10 (5.26) 
gliquidone  31 (16.32) 
Glimepiride* 89 (46.84) 
Pioglitazone  2 (1.05) 
Acarbose  7 (3.68) 
Linagliptine 36 (18.95) 
Sitagliptine  43 (22.63) 
Vidagliptine 14 (7.37) 
Insulin  15 (7.89) 
Combined antidiabetic agents 
Acarbose + Glimepiride 2 (1.05) 
Acarbose + Glimepiride + Linaglibtin 1 (0.53) 
Acarbose + Glimepiride + Metformin  2 (1.05) 
Gliquidone + Glimepiride + Metformin + 
Linaglibtin 
1 (0.53) 
Gliquidone + Linaglibtin 2 (1.05) 
Gliquidone + Sitaglipin 2 (1.05) 
Gliquidone + Metformin + Linaglibtin 4 (2.11) 
Gliquidone + Metformin + Linaglibtin + 
Sitaglipin + Vidaglibtin 
4 (2.11) 
Glimepiride + Metformin + Linaglibtin 6 (3.16) 
Glimepiride + Metformin + Sitaglipin 8 (4.21) 
Glimepiride + Metformin + Vidaglibtin + 
Sitaglipin 
4 (2.11) 
Glimepiride + Metformin + Linaglibtin + 
Sitaglipin 
4 (2.11) 
Glimepiride + Linaglibtin 5 (2.63) 
Glimepiride + Sitaglipin  2 (1.05) 
Glimepiride + Pioglitazon 1 (0.53) 
Metformin + Glibenklamid  4 (2.11) 
Metformin + Glimenklamid + Glimepiride 4 (2.11) 
Metformin + Gliquidone 6 (3.16) 
Metformin + Gliquidone + Glimepiride  6 (3.16) 
Metformin + Glimepiride 37 (19.47) 
Metformin + Linaglibtin 6 (3.16) 
Metformin + Sitaglipin 10 (5.26) 
Metformin + Vidaglibtin 4 (2.11) 
Insulin + Acarbose 1 (0.53) 
Insulin + Gliquidone  3 (1.68) 
Insulin + Gliquidone + Linaglibtin 1 (0.53) 
Insulin + Glimepiride + Metformin 2 (1.05) 
Insulin + Glimepiride + Metformin + 
Sitaglipin 
1 (0.53) 
Insulin + Metformin 5 (2.63) 
Insulin + Metformin + Sitaglipin 1 (0.53) 
*  The most prescribed antidiabetic agents 
Hypertension is a common comorbidity in diabetic 
patients, and adequate blood pressure control 
significantly reduces the risk of macrovascular and 
microvascular complications. More than half of the 
participants (63.26%) received more than one 
antihypertensive agent. This study is in line with Hussen 
et al. (2017) who reported more than half of patients 
(62.7%) received a combination of two or more 
antihypertensive drugs. Amlodipine (34.74%) followed 
by furosemide (17.90%), candesartan (16.84%), captopril 
(13.68%), and bisoprolol (12.63%) were the five most 
prescribed antihypertensive agents, as shown in Table II. 
This result is supported by Zazuli et al. (2017) who 
reported amlodipine to be the most prescribed 
antihypertensive agent in diabetic patients with 
hypertension. However, these results contradict with 
study by Yimama et al. (2018), Argaw et al. (2019), and 
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Ayele et al. (2018) who reported enalapril as the most 
commonly prescribed antihypertensive drug. This study 
also contrasts with Hussen et al. (2017) who reported the 
most commonly prescribed antihypertensive medication 
was hydrochlorothiazide (41.4%). These results confirm 
that country differences play a very important role in the 
most prescribed type of antihypertensive agents. 
The target blood pressure in T2DM with hypertension is 
130/80 mmHg. Initial treatment for T2DM patients 
depends on the severity of hypertension. Those who 
have blood pressure between 140/90 to 159/99 mmHg 
should start with monotherapy. Angiotensin-converting 
enzyme (ACE) inhibitors or Angiotensin II receptor 
blockers (ARB) are recommended as initial treatment in 
diabetic patients with hypertension. For patients with 
blood pressure ≥160/100 mmHg, initial therapy with 
two antihypertensives is recommended. However, the 
use of both ACE inhibitors and ARBs in combination is 
not recommended due to increased side effects such as 
hyperkalemia, syncope, and acute kidney injury (de Boer 
et al., 2017). The combination of ACE inhibitors or ARBs 
with calcium-channel blockers (CCBs) is preferred for 
nephroprotective, angioprotective, and metabolic effects. 
This drug is used for normotensive T2DM patients for 
albuminuria, retinopathy, and stroke prevention (Farský 
et al., 2018). 
Table II. Patterns prescription of antihypertensive agents in 
T2DM with hypertension (n = 190) 
Variable category N (%) 
Number of prescription  
Monotherapy  85 (44.74) 
2 anti-hypertension agents 71 (37.37) 
3 anti-hypertension agents 22 (11.58) 
4 anti-hypertension agents 10 (5.26) 
5 anti-hypertension agents 2 (1.05) 
Type of antihypertensive agents 
Captopril* 26 (13.68) 
Ramipril  3 (1.58) 
Candesartan* 32 (16.84) 
Irbesartan  8 (4.21) 
Telmisartan  8 (4.21) 
Valsartan  5 (2.63) 
Furosemide* 34 (17.90) 
Bisoprolol* 24 (12.63) 
Amlodipine* 66 (34.74) 
Diltiazem  3 (1.58) 
Atenolol  1 (0.53) 
Carvedilol  6 (3.16) 
Hydrochlorothiazide 1 (0.53) 
Losartan  1 (0.53) 
Spironolakton  6 (3.16) 
Nifedipin  6 (3.16) 
Popranolol  1 (0.53) 
Combined antihypertensive agents 
Amlodipine + Atenolol 1 (0.53) 
Amlodipine + bisoprolol  9 (4.74) 
Amlodipine + Bisoprolol + Furosemida  1 (0.53) 
Amlodipin + Bisoprolol + Irbesartan + 
Captopril 
2 (1.05) 
Amlodipin + Bisoprolol + Candesartan + 
Ramipril  
1 (0.53) 
Amlodipin + Bisoprolol + Captopril   2 (1.05) 
Amlodipin + Furosemida Injection 4 (2.11) 
Amlodipin + Furosemida  2 (1.05) 
Amlodipin + Irbesartan 6 (3.16) 
Amlodipin + Candesartan  8 (4.21) 
Amlodipin + Irbesartan + Spironolakton  1 (0.53) 
Amlodipin + Candesartan + Bisoprolol 1 (0.53) 
Amlodipin + Candesartan + Furosemida 1 (0.53) 
Amlodipin + Captopril 11 (5.79) 
Amlodipin + Captopril + Furosemid 1 (0.53) 
Amlodipin + Captopril + Losartan 1 (0.53) 
Amlodipin + Captopril + Nifedipin 1 (0.53) 
Amlodipin + Carvedilol + Furosemid 1 (0.53) 
Amlodipin + Propranolol 1 (0.53) 
Amlodipin + Telmisartan + Furosemid 
Injection 
1 (0.53) 
Amlodipin + Valsartan  3 (1.58) 
Bisoprolol + Diltiazem  1 (0.53) 
Bisoprolol + Furosemid Injection 3 (1.58) 
Bisoprolol + Furosemida Injection + 
Telmisartan 
2 (1.05) 
Bisoprolol + Irbesartan  1 (0.53) 
Bisoprolol + Candesartan 1 (0.53) 
Bisoprolol + Candesartan + Furosemida  1 (0.53) 
Bisoprolol + Candesartan + Furosemida + 
Furosemida Injection 
1 (0.53) 
Bisoprolol + Candesartan + Furosemida + 
Spironolakton 
1 (0.53) 
Bisoprolol + Carvedilol + Candesartan + 
Furosemida + Furosemida Injection 
1 (0.53) 
Bisoprolol + Candesartan + Nifedipine  1 (0.53) 
Bisoprolol + Captopril 5 (2.63) 
Bisoprolol + Captopril + Furosemida Injection 1 (0.53) 
Bisoprolol + Captopril + Nifedipine  2 (1.05) 
Bisoprolol + Captopril + Nifedipine + 
Irbesartan + Diltiazem 
1 (0.53) 
Bisoprolol + Ramipril  1 (0.53) 
Bisoprolol + Telmisartan 1 (0.53) 
Furosemida injection + Furosemida + 
Carvedilol + Spironolakton 
1 (0.53) 
Furosemida injection + Captopril  1 (0.53) 
Furosemida injection + Telmisartan  1 (0.53) 
Furosemida + Candesartan 1 (0.53) 
Furosemida + Spironolakton + Carvedilol 1 (0.53) 
Irbesartan + Nifedipin  1 (0.53) 
Candesartan + Furosemida injection  2 (1.05) 
Candesartan + Furosemida + Furosemida 
injection 
1 (0.53) 
Candesartan + Captopril  2 (1.05) 
Candesartan + Nifedipine 1 (0.53) 
Candesartan + Valsartan + Furosemida + 
Spironolakton  
2 (1.05) 
Captopril + Furosemida innjection 1 (0.53) 
Captopril + Irbesartan + Furosemida injection 1 (0.53) 
Captopril + Telmisartan + Furosemida  1 (0.53) 
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Captopril + Nifedipine 1 (0.53) 
Ramipril + Furosemida injection 1 (0.53) 
Furosemida + Spironolakton 1 (0.53) 
Telmisartan + Carvedilol + Furosemida + 
Furosemida injection 
1 (0.53) 
Valsartan + Hydrochlorothiazide 1 (0.53) 
Valsartan + Carvedilol  1 (0.53) 
*  The most prescribed antihypertensive agents 
Treatment of diabetes with comorbid hypertension in 
COVID-19 
At present, in the condition of the pandemic novel 
coronavirus 2019 (COVID-19), diabetic comorbidities are 
one of the risk factors for hospitalization and death due to 
COVID-19. Diabetes was a comorbidity in 22% of non-
survivors in a study of 52 intensive care patients (Yang et 
al., 2020). Other comorbidities such as hypertension in 
about 20% of cases, cardiovascular disease (16%), and 
lung disease (6%) are other common comorbidities 
(Ruan et al., 2020; Wu et al., 2020; Li et al., 2020). In fact, 
patients with T2DM are at high risk for infection and 
suffer severe symptoms of COVID-19, including 
bacterial pneumonia which can be reduced through 
good blood glucose control (Critchley et al., 2018). Basal-
bolus insulin or insulin pump therapy will be preferred 
in T2DM patients to avoid hyperglycemia and 
ketoacidosis. It also requires monitoring of blood glucose 
levels and setting insulin doses to prevent hypoglycemia 
(Apicella et al., 2020). 
The other most common comorbidities in COVID-19 
patients besides diabetes are hypertension. Both of these 
diseases are often treated with ACE inhibitors and ARBs. 
COVID-19 binds to target cells via angiotensin-
converting enzyme 2 (ACE2) expressed in epithelial cells 
in the lungs, blood vessels, and in the intestine (Wan et al., 
2020). Patients treated with ACE inhibitors and ARBs 
showed an increase in the number of ACE2 (Li et al., 
2017). Therefore, there are two hypothetical drugs of 
choice in comorbid hypertension in COVID-19 
infections. Hypothesis by Fang et al. (2020) suggests that 
COVID-19 patients with hypertension, diabetes, and 
cardiovascular disease treated with ACE inhibitors and 
ARBs should monitor ACE2 counts or consider other 
antihypertensives, CCBs as therapies that are known to 
not increase the amount of ACE2 expressed and their 
activities because it can be an appropriate alternative 
depending on the patient's condition. Another 
hypothesis by Singh et al. (2020) emphasize because of the 
lack of evidence for the benefits or dangers of using ACE 
inhibitors and ARBs in patients with diabetes and 
hypertension with COVID-19, it makes sense for patients 
to continue using both. This is the following 
recommendation by the European Society of Cardiology, 
Hypertension Canada, The Canadian Cardiovascular 
Society, the UK Renal Association, the International 
Society of Hypertension, the European Society of 
Hypertension, and the American Heart Association. 
Drug therapy problems 
Among the participants, more than half of the 
participants (56.84%) have at least one of DTPs. The 
number of DTPs finding is lower than Yimama et al. 
(2018) and Shareef et al. (2015), where 82% and 71.1% of 
participants at least had one of DTPs, respectively. A total 
of 108 DTPs was identified across the six categories as 
presented in Table III. Adverse drug reaction was the 
highest 51 cases (47.22%), followed by ineffective drug 
therapy 32 cases (29.63%), unnecessary drug therapy 19 
cases (17.6%), as well as need additional therapy, dose too 
low, and dose too high, each of them with two cases 
(1.85%). These study findings supported by Nazilah et al. 
(2017), Lira et al. (2017), and Hartuti et al. (2019), which 
highlighted adverse drug reaction and drug interaction 
as most common DTPs occurred during polypharmacy 
treatment prescribed. Potential adverse drug reaction 
event in the combination of medications treatment higher 
than single medication treatment. This study contrasting 
to another study who reported the most common drug 
therapy problems was the need for additional drug 
therapy (Yimama et al., 2018; Argaw et al., 2019; Hussen et 
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al., 2017). Percentage of DTP events in this study is 
visualized in Figure 1. 
Table III. Causes of DTPs among T2DM with hypertension in 
hospital setting (n= 108) 
Category of DTPs Causes of DTPS Frequency (%) 
Adverse drug 
reaction 
Drug interaction 32 (29.63) 
Contraindication 19 (17.59) 
Ineffective drug 
therapy 
Not the most 
effective for 
medical problem 
32 (29.63) 
Unnecessary drug 
therapy 
Not valid medical 
indication for the 
drug therapy at 
this time 
19 (17.60) 
Need additional 
therapy 
To attain 
synergistic/ 
additive effect 
2 (1.85) 
Dosage too low Dosage regime not 
frequent enough 
2 (1.85) 
Dosage too high Dosage regime too 
frequent 
2 (1.85) 
 
 
Figure 1. Percentage of DTP events 
 
Among these DTPs, adverse drug reactions were the 
most common DTP category (47.22%). The possible 
causes of this DTPs were drug interaction (29.63%) and 
contraindications (17.59%). Potential drug interactions 
include antidiabetic and antibiotic, antihypertensive and 
antifungal, and fellow antihypertensive. Drug 
interactions may occur in the pharmacokinetic phase 
caused by inhibitory metabolic mechanisms. Possible 
side effects are an increased risk of heart blockage and an 
increased effect of hypoglycemia (Baxter, 2009). The 
possible drug interactions that occur are presented in 
Table IV. 
Table IV. Determinant of drug-drug interaction in T2DM 
patients with hypertension (n= 32) 
Drug-drug 
interaction 
Mechanism Category N 
Glimepiride- 
Levofloxacin/ 
Moxifloxacin 
Potential to 
elevate 
hypoglycemia 
effect 
Pharmacokinetics 12  
Amlodipine-
Fluconazole 
Decrease 
amlodipine 
metabolism, 
might be 
increase risk of 
heart block 
Pharmacokinetics 3 
Atenolol-
Amlodipine  
Increase risk of 
heart block  
Pharmacokinetics 1 
Bisoprolol-
Diltiazem 
Increase risk of 
heat block 
Pharmacokinetics 1 
Bisoprolol-
Nifedipine 
Increase risk of 
heart block 
Pharmacokinetics 2 
Bisoprolol-
Insulin 
Potential to 
elevate 
hypoglycemia 
effect 
Pharmacokinetics 3 
Ramipril-
Spironolacton 
Potential to 
elevate 
hypoglycemia 
effect 
Pharmacokinetics 1 
Bisoprolol-
Amlodipine 
Increase risk of 
heart block 
Pharmacokinetics 9 
 
In this study, ineffective drug therapy (29.63%) and 
unnecessary drug therapy (17.60%) were the second and 
third most potential DTPs, respectively. Ineffective drug 
therapy was found in 32 T2DM patients with 
hypertension who received furosemide because the 
antihypertensive treatment might be involved in glucose 
tolerance. Meanwhile, the drug of choice for 
hypertension with diabetes based on guidelines 
recommends the use of ACE inhibitors or ARBs or non-
dihydropyridine CCBs (James et al., 2014). Unnecessary 
drug therapy in 10 patients who received antibiotics and 
nine patients received gastrointestinal drugs without 
clear indications. Need additional therapy, the dose is too 
low, and the dose is too high, each only 1.85% of the total 
DTPs. This insignificant amount might be due to the 
study being conducted in patients who were 
hospitalized, where there are better care and 
collaboration of health professionals with supervised 
drug administration. Because of the retrospective data 
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source in this study, non-compliance with treatment was 
excluded to be assessed in this study. 
There are several limitations to this study. First, this study 
is not from an evaluation of prospective structures or 
interviews with patients. Second, this study did not 
assess treatment compliance among T2DM patients with 
hypertension. However, this study has several 
advantages, including this research which is a pioneer in 
the study of DTPs assessment in T2DM patients with 
hypertension. Besides, this study proposes insights for 
the drug of choice in T2DM patients and hypertension 
who are infected with COVID-19. 
 
CONCLUSION 
This study highlights the majority of T2DM patients with 
comorbid hypertension who have at least one drug 
therapy problem that might have an impact on treatment 
goals and treatment costs. The role of pharmacists in drug 
management by detecting, preventing, and solving drug 
therapy problems can be encouraged to deal with these 
problems. 
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